Kazakhstan is in talks with the world's leading pharmaceutical companies to implement 13 investment projects. Their cost will exceed 17 billion tenge, the country's Health Minister Azhar Giniyat announced at the Government’s meeting. According to her, special attention will be paid to cluster development, production of expensive innovative products and digitalization of the industry. There are currently three cities in consideration for the location of cluster zones, namely Aktobe, Nur-Sultan and Shymkent. These regions are attractive due to the fact that they have production sites and leading medical universities on their territory. It is expected that a full cycle of pharmaceutical production will be established there.
“Kazakhstan is interested in attracting investments and advanced technologies necessary for the successful modernization of the economy. At present, negotiations are underway at various stages with seven big pharma companies on 13 investment projects under contract production. These are Roche, Novo Nordisk, AstraZeneca, Sandoz, Takeda, Pfizer, and Atabay Pharmaceuticals and Fine Chemicals. The cost of investment will amount to more than 17 billion tenge,” said Azhar Giniyat, Kazakh Health Minister.
The Head of State instructed to increase the share of domestic production in the pharmaceutical market to 50 percent by 2025. To this end, a Comprehensive Plan for the Development of the Industry has already been approved.
Translation by Assem Zhanmukhanova
Editing by Saule Mukhamejanova
Web-editor: Admin
Related Articles
